ID	start_index	end_index	token	lemma	POS
1	24	34	Background	background	NNP
2	43	50	Primary	primary	JJ
3	51	58	Sjögren	sjögren	NNP
5	61	69	syndrome	syndrome	NN
7	71	72	1	1	CD
9	73	75	SS	ss	NNP
11	77	79	is	be	VBZ
12	80	81	a	a	DT
13	82	90	systemic	systemic	JJ
14	99	109	autoimmune	autoimmune	JJ
15	110	118	disorder	disorder	NN
16	119	132	characterized	characterize	VBN
17	133	135	by	by	IN
18	136	139	dry	dry	JJ
19	140	144	eyes	eye	NNS
21	154	174	keratoconjunctivitis	keratoconjunctivitis	NNS
22	175	180	sicca	sicca	NN
25	183	186	dry	dry	JJ
26	187	192	mouth	mouth	NN
28	194	204	xerostomia	xerostomium	NN
30	206	208	as	as	RB
31	217	221	well	well	RB
32	222	224	as	as	IN
33	225	236	involvement	involvement	NN
34	237	239	of	of	IN
35	240	245	other	other	JJ
36	246	254	exocrine	exocrine	NN
37	255	261	glands	gland	NNS
39	263	268	While	while	IN
40	269	270	1	1	CD
42	271	273	SS	ss	NNP
43	274	276	is	be	VBZ
44	285	294	typically	typically	RB
45	295	305	considered	consider	VBN
46	306	308	an	an	DT
47	309	319	autoimmune	autoimmune	JJ
48	320	333	exocrinopathy	exocrinopathy	NN
50	335	338	the	the	DT
51	347	353	immune	immune	JJ
52	354	365	destruction	destruction	NN
53	366	369	can	can	MD
54	370	375	often	often	RB
55	376	382	extend	extend	VB
56	383	385	to	to	TO
57	386	392	affect	affect	VB
58	393	405	non-exocrine	non-exocrine	JJ
59	414	420	organs	organ	NNS
61	422	428	Around	around	IN
62	429	431	25	25	CD
64	434	436	of	of	IN
65	437	445	patients	patient	NNS
66	446	450	with	with	IN
67	451	452	1	1	CD
69	453	455	SS	ss	NNP
70	456	459	can	can	MD
71	460	467	present	present	VB
72	468	472	with	with	IN
73	481	492	involvement	involvement	NN
74	493	495	of	of	IN
75	496	501	other	other	JJ
76	502	508	organs	organ	NNS
77	509	513	such	such	JJ
78	514	516	as	as	IN
79	517	520	the	the	DT
80	521	528	thyroid	thyroid	NN
82	530	537	central	central	JJ
83	546	553	nervous	nervous	JJ
84	554	560	system	system	NN
86	562	567	lungs	lung	NNS
88	569	575	kidney	kidney	NN
89	576	579	and	and	CC
90	580	585	liver	liver	NN
92	587	590	The	the	DT
93	591	602	association	association	NN
94	603	605	of	of	IN
95	614	619	liver	liver	NN
96	620	627	disease	disease	NN
97	628	631	and	and	CC
98	632	633	1	1	CD
100	634	636	SS	ss	NNP
101	637	640	was	be	VBD
102	641	650	suggested	suggest	VBN
103	651	655	more	more	JJR
104	656	660	than	than	IN
105	661	663	40	40	CD
106	664	669	years	year	NNS
107	670	673	ago	ago	RB
109	684	685	1	1	CD
112	690	695	While	while	IN
113	696	701	liver	liver	NN
114	702	713	involvement	involvement	NN
115	714	716	in	in	IN
116	717	718	1	1	CD
118	719	721	SS	ss	NNP
119	722	725	has	have	VBZ
120	726	730	been	be	VBN
121	731	741	considered	consider	VBN
123	751	755	rare	rare	JJ
126	759	760	2	2	CD
128	763	767	only	only	RB
129	768	769	a	a	DT
130	770	773	few	few	JJ
131	774	782	clinical	clinical	JJ
132	783	790	studies	study	NNS
133	791	803	specifically	specifically	RB
134	812	819	address	address	VBP
135	820	824	this	this	DT
136	825	837	complication	complication	NN
137	838	841	and	and	CC
138	842	850	evaluate	evaluate	VB
139	851	854	the	the	DT
140	855	866	association	association	NN
141	867	869	of	of	IN
142	878	883	liver	liver	NN
143	884	892	function	function	NN
144	893	898	tests	test	VBZ
145	899	912	abnormalities	abnormality	NNS
146	913	917	with	with	IN
147	918	921	the	the	DT
148	922	930	severity	severity	NN
149	931	933	of	of	IN
150	942	943	1	1	CD
152	944	946	SS	ss	NNP
154	949	950	3	3	CD
155	951	952	4	4	CD
156	953	954	5	5	CD
157	955	956	6	6	CD
160	969	974	Liver	liver	NNP
161	975	983	diseases	disease	NNS
162	984	994	associated	associate	VBN
163	995	999	with	with	IN
164	1000	1001	1	1	CD
166	1002	1004	SS	ss	NNP
167	1005	1012	include	include	VBP
168	1013	1020	primary	primary	JJ
169	1029	1036	biliary	biliary	JJ
170	1037	1046	cirrhosis	cirrhosis	NNS
172	1048	1051	PBC	pbc	NNP
175	1053	1063	autoimmune	autoimmune	JJ
176	1064	1075	cholangitis	cholangitis	NNS
178	1078	1079	8	8	CD
179	1080	1081	9	9	CD
180	1082	1084	10	10	CD
183	1097	1107	autoimmune	autoimmune	JJ
184	1108	1117	hepatitis	hepatitis	NN
186	1120	1121	5	5	CD
187	1122	1123	6	6	CD
190	1128	1133	viral	viral	JJ
191	1134	1143	hepatitis	hepatitis	NN
194	1147	1150	and	and	CC
198	1164	1166	11	11	CD
199	1167	1169	12	12	CD
200	1170	1172	13	13	CD
201	1173	1175	14	14	CD
202	1176	1178	15	15	CD
203	1179	1181	16	16	CD
204	1182	1184	17	17	CD
205	1185	1187	18	18	CD
206	1188	1190	19	19	CD
207	1191	1193	20	20	CD
208	1194	1196	21	21	CD
211	1201	1211	sclerosing	sclerose	VBG
212	1212	1223	cholangitis	cholangitis	NNS
214	1234	1236	22	22	CD
217	1241	1244	and	and	CC
218	1245	1252	nodular	nodular	NN
219	1253	1265	regenerative	regenerative	JJ
220	1266	1277	hyperplasia	hyperplasium	NN
222	1280	1282	23	23	CD
225	1287	1289	In	in	IN
226	1298	1306	addition	addition	NN
228	1308	1315	chronic	chronic	JJ
229	1316	1327	lymphocytic	lymphocytic	JJ
230	1328	1340	sialadenitis	sialadenitis	NNS
231	1341	1344	has	have	VBZ
232	1345	1349	been	be	VBN
233	1350	1355	found	find	VBN
234	1364	1366	in	in	IN
235	1367	1375	patients	patient	NNS
236	1376	1380	with	with	IN
237	1381	1390	different	different	JJ
238	1391	1396	types	type	NNS
239	1397	1399	of	of	IN
240	1400	1405	liver	liver	NN
241	1406	1415	cirrhosis	cirrhosis	NNS
243	1418	1420	16	16	CD
244	1421	1423	17	17	CD
245	1432	1434	18	18	CD
246	1435	1437	19	19	CD
247	1438	1440	20	20	CD
248	1441	1443	21	21	CD
249	1444	1446	22	22	CD
250	1447	1449	23	23	CD
251	1450	1452	24	24	CD
254	1465	1467	We	we	PRP
255	1468	1474	report	report	VBP
256	1475	1478	the	the	DT
257	1479	1486	results	result	NNS
258	1487	1489	of	of	IN
259	1490	1491	a	a	DT
260	1492	1498	review	review	NN
261	1499	1501	of	of	IN
262	1502	1507	cases	case	NNS
263	1508	1518	undertaken	undertake	VBN
264	1519	1521	to	to	TO
265	1530	1539	determine	determine	VB
266	1540	1543	the	the	DT
267	1544	1554	prevalence	prevalence	NN
268	1555	1557	of	of	IN
269	1558	1566	abnormal	abnormal	JJ
270	1567	1572	liver	liver	NN
271	1573	1581	function	function	NN
272	1582	1587	tests	test	NNS
274	1597	1601	LFTs	lft	NNP
276	1603	1606	and	and	CC
277	1607	1612	liver	liver	NN
278	1613	1620	disease	disease	NN
279	1621	1623	in	in	IN
280	1624	1632	patients	patient	NNS
281	1633	1637	with	with	IN
282	1638	1639	1	1	CD
284	1640	1642	SS	ss	NNP
285	1643	1651	referred	refer	VBD
286	1652	1654	to	to	TO
287	1663	1664	a	a	DT
288	1665	1673	tertiary	tertiary	JJ
289	1674	1678	care	care	NN
290	1679	1685	center	center	NN
291	1686	1689	and	and	CC
292	1690	1693	the	the	DT
293	1694	1705	association	association	NN
294	1706	1708	of	of	IN
295	1709	1717	abnormal	abnormal	JJ
296	1718	1722	LFTs	lft	NNP
297	1731	1735	with	with	IN
298	1736	1741	other	other	JJ
299	1742	1750	systemic	systemic	JJ
300	1751	1759	features	feature	NNS
301	1760	1763	and	and	CC
302	1764	1776	autoimmunity	autoimmunity	NN
303	1777	1784	markers	marker	NNS
304	1785	1787	of	of	IN
305	1796	1797	1	1	CD
307	1798	1800	SS	ss	NNP
309	1824	1831	Methods	method	NNP
310	1851	1862	Statistical	statistical	NNP
311	1863	1871	analysis	analysis	NN
312	1882	1885	The	the	DT
313	1886	1897	statistical	statistical	JJ
314	1898	1906	analysis	analysis	NN
315	1907	1915	included	include	VBD
316	1916	1927	descriptive	descriptive	JJ
317	1928	1936	measures	measure	NNS
319	1948	1953	means	means	VBZ
321	1955	1963	standard	standard	JJ
322	1964	1974	deviations	deviation	NNS
323	1975	1978	and	and	CC
324	1979	1985	ranges	range	NNS
327	1988	1998	Comparison	comparison	NNP
328	1999	2001	of	of	IN
329	2012	2019	results	result	NNS
330	2020	2022	of	of	IN
331	2023	2031	patients	patient	NNS
332	2032	2036	with	with	IN
333	2037	2040	and	and	CC
334	2041	2048	without	without	IN
335	2049	2054	liver	liver	NN
336	2055	2062	disease	disease	NN
337	2063	2066	was	be	VBD
338	2077	2081	done	do	VBN
339	2082	2087	using	use	VBG
340	2088	2095	t-tests	t-test	JJ
341	2096	2098	of	of	IN
342	2099	2109	continuous	continuous	JJ
343	2110	2119	variables	variable	NNS
344	2120	2123	and	and	CC
345	2124	2130	Fisher	fisher	NNP
347	2143	2148	exact	exact	JJ
348	2149	2153	test	test	NN
349	2154	2156	or	or	CC
351	2158	2159	2	2	CD
352	2160	2163	for	for	IN
353	2164	2173	categoric	categoric	JJ
354	2174	2182	measures	measure	NNS
356	2215	2222	Results	result	NNS
357	2231	2233	Of	of	IN
358	2234	2237	the	the	DT
359	2238	2241	115	115	CD
360	2242	2248	charts	chart	NNS
361	2249	2257	reviewed	review	VBN
363	2259	2261	73	73	CD
364	2262	2267	cases	case	NNS
366	2269	2271	55	55	CD
367	2272	2277	women	woman	NNS
368	2278	2281	and	and	CC
369	2282	2284	18	18	CD
370	2293	2296	men	man	NNS
372	2298	2304	median	median	JJ
373	2305	2308	age	age	NN
374	2309	2311	53	53	CD
376	2313	2322	fulfilled	fulfill	VBN
377	2323	2327	EECC	eecc	NNP
378	2328	2331	for	for	IN
379	2332	2333	1	1	CD
381	2334	2336	SS	ss	NNP
382	2337	2340	and	and	CC
383	2341	2345	were	be	VBD
384	2354	2363	initially	initially	RB
385	2364	2372	included	include	VBN
386	2373	2376	for	for	IN
387	2377	2385	analysis	analysis	NN
389	2387	2389	Of	of	IN
390	2390	2393	the	the	DT
391	2394	2396	73	73	CD
392	2397	2405	patients	patient	NNS
394	2407	2408	a	a	DT
395	2409	2411	54	54	CD
397	2421	2423	of	of	IN
398	2424	2428	them	them	PRP
400	2430	2432	40	40	CD
401	2433	2441	patients	patient	NNS
403	2443	2447	have	have	VBP
404	2448	2451	had	have	VBD
405	2452	2453	a	a	DT
406	2454	2462	salivary	salivary	JJ
407	2463	2468	gland	gland	NN
408	2469	2475	biopsy	biopsy	NN
409	2484	2493	performed	perform	VBN
411	2495	2497	In	in	IN
412	2498	2501	all	all	PDT
413	2502	2507	these	these	DT
414	2508	2516	patients	patient	NNS
416	2518	2521	the	the	DT
417	2522	2528	biopsy	biopsy	NN
418	2529	2538	confirmed	confirm	VBD
419	2539	2542	the	the	DT
420	2551	2560	diagnosis	diagnosis	NN
421	2561	2563	of	of	IN
422	2564	2571	Sjögren	sjögren	NNP
424	2574	2582	syndrome	syndrome	NN
426	2584	2587	All	all	DT
427	2588	2596	patients	patient	NNS
428	2597	2604	studied	study	VBN
429	2605	2608	had	have	VBD
430	2617	2626	objective	objective	NN
431	2627	2635	evidence	evidence	NN
432	2636	2638	of	of	IN
433	2639	2640	1	1	CD
435	2641	2643	SS	ss	NNP
437	2645	2654	including	include	VBG
438	2655	2675	keratoconjunctivitis	keratoconjunctivitis	NNS
439	2684	2689	sicca	sicca	NN
441	2691	2699	positive	positive	JJ
442	2700	2706	labial	labial	NN
443	2707	2715	salivary	salivary	JJ
444	2716	2721	gland	gland	NN
445	2722	2728	biopsy	biopsy	NN
447	2738	2752	autoantibodies	autoantibody	NNS
448	2753	2756	and	and	CC
450	2757	2759	or	or	CC
451	2760	2768	salivary	salivary	JJ
452	2769	2774	gland	gland	NN
453	2775	2787	hypofunction	hypofunction	NN
455	2789	2791	We	we	PRP
456	2800	2808	excluded	exclude	VBD
457	2809	2814	those	those	DT
458	2815	2823	patients	patient	NNS
459	2824	2831	without	without	IN
460	2832	2837	these	these	DT
461	2838	2847	objective	objective	NN
462	2848	2856	criteria	criterion	NNS
463	2857	2859	of	of	IN
464	2868	2869	1	1	CD
466	2870	2872	SS	ss	NNP
467	2873	2876	and	and	CC
468	2877	2881	also	also	RB
469	2882	2887	those	those	DT
470	2888	2891	who	who	WP
471	2892	2895	did	do	VBD
472	2896	2899	not	not	RB
473	2900	2907	fulfill	fulfill	VB
474	2908	2912	EECC	eecc	NNP
475	2913	2921	criteria	criterion	NNS
477	2931	2934	The	the	DT
478	2935	2939	mean	mean	JJ
479	2940	2943	age	age	NN
480	2944	2946	at	at	IN
481	2947	2951	time	time	NN
482	2952	2954	of	of	IN
483	2955	2960	onset	onset	NN
484	2961	2963	of	of	IN
485	2964	2971	disease	disease	NN
486	2972	2975	was	be	VBD
487	2976	2978	45	45	CD
489	2981	2985	20.5	20.5	CD
490	2994	2999	years	year	NNS
491	3000	3003	old	old	JJ
492	3004	3007	and	and	CC
493	3008	3015	disease	disease	NN
494	3016	3024	duration	duration	NN
495	3025	3028	was	be	VBD
496	3029	3032	4.9	4.9	CD
497	3033	3038	years	year	NNS
499	3041	3044	4.5	4.5	CD
500	3045	3050	years	year	NNS
502	3060	3064	mean	mean	VB
504	3067	3072	range	range	NN
507	3075	3080	Liver	liver	NNP
508	3081	3089	function	function	NN
509	3090	3095	tests	test	NNS
510	3096	3099	had	have	VBD
511	3100	3104	been	be	VBN
512	3105	3115	determined	determine	VBN
513	3116	3118	in	in	IN
514	3127	3129	59	59	CD
515	3130	3138	patients	patient	NNS
517	3140	3144	80.8	80.8	CD
520	3148	3151	and	and	CC
521	3152	3160	abnormal	abnormal	JJ
522	3161	3166	liver	liver	NN
523	3167	3175	function	function	NN
524	3176	3181	tests	test	NNS
525	3182	3186	were	be	VBD
526	3195	3200	found	find	VBN
527	3201	3203	in	in	IN
528	3204	3206	29	29	CD
529	3207	3209	of	of	IN
530	3210	3213	the	the	DT
531	3214	3216	59	59	CD
532	3217	3225	patients	patient	NNS
534	3227	3231	49.1	49.1	CD
538	3236	3243	Further	further	RB
539	3244	3252	analysis	analysis	NN
540	3261	3264	was	be	VBD
541	3265	3269	then	then	RB
542	3270	3280	undertaken	undertake	VBN
543	3281	3283	in	in	IN
544	3284	3289	those	those	DT
545	3290	3298	patients	patient	NNS
546	3299	3301	in	in	IN
547	3302	3306	whom	whom	WP
548	3307	3311	LFTs	lft	NNP
549	3312	3315	had	have	VBD
550	3316	3320	been	be	VBN
551	3329	3337	measured	measure	VBN
553	3339	3342	The	the	DT
554	3343	3351	clinical	clinical	JJ
555	3352	3355	and	and	CC
556	3356	3366	laboratory	laboratory	NN
557	3367	3382	characteristics	characteristic	NNS
558	3383	3385	of	of	IN
559	3394	3399	these	these	DT
560	3400	3408	patients	patient	NNS
561	3409	3412	are	be	VBP
562	3413	3418	shown	show	VBN
563	3419	3421	in	in	IN
564	3422	3428	Tables	table	NNP
565	3429	3430	2	2	CD
566	3430	3433	and	and	CC
567	3434	3435	3	3	CD
569	3445	3448	For	for	IN
570	3449	3454	these	these	DT
571	3455	3457	SS	ss	NNP
572	3458	3466	patients	patient	NNS
573	3467	3474	studied	study	VBN
575	3476	3484	abnormal	abnormal	JJ
576	3485	3489	LFTs	lft	NNP
577	3490	3494	were	be	VBD
578	3495	3499	more	more	RBR
579	3508	3514	common	common	JJ
580	3515	3519	than	than	IN
581	3520	3523	any	any	DT
582	3524	3529	other	other	JJ
583	3530	3539	potential	potential	JJ
584	3540	3552	non-exocrine	non-exocrine	JJ
585	3553	3561	features	feature	NNS
586	3562	3564	of	of	IN
587	3573	3575	SS	ss	NNP
589	3577	3585	Clinical	clinical	NNP
590	3586	3594	evidence	evidence	NN
591	3595	3597	of	of	IN
592	3598	3603	liver	liver	NN
593	3604	3611	disease	disease	NN
595	3613	3620	defined	define	VBN
596	3621	3623	in	in	IN
597	3624	3631	methods	method	NNS
598	3640	3647	section	section	NN
600	3649	3652	was	be	VBD
601	3653	3658	found	find	VBN
602	3659	3661	in	in	IN
603	3662	3664	12	12	CD
604	3665	3673	patients	patient	NNS
606	3675	3679	20.3	20.3	CD
610	3683	3686	all	all	DT
611	3687	3689	of	of	IN
612	3690	3694	whom	whom	WP
613	3695	3698	had	have	VBD
614	3707	3715	abnormal	abnormal	JJ
615	3716	3721	liver	liver	NN
616	3722	3730	function	function	NN
617	3731	3736	tests	test	NNS
619	3738	3741	Two	two	CD
620	3742	3748	deaths	death	NNS
621	3749	3757	occurred	occur	VBD
622	3758	3760	in	in	IN
623	3761	3764	the	the	DT
624	3773	3783	population	population	NN
625	3784	3791	studied	study	VBD
627	3793	3797	both	both	DT
628	3798	3808	attributed	attribute	VBD
629	3809	3811	to	to	TO
630	3812	3817	liver	liver	NN
631	3818	3825	failure	failure	NN
633	3827	3829	An	an	DT
634	3838	3848	additional	additional	JJ
635	3849	3856	patient	patient	NN
636	3857	3865	required	require	VBD
637	3866	3867	a	a	DT
638	3868	3873	liver	liver	NN
639	3874	3884	transplant	transplant	NN
641	3886	3888	In	in	IN
642	3889	3892	all	all	DT
643	3901	3906	cases	case	NNS
645	3908	3911	the	the	DT
646	3912	3921	diagnosis	diagnosis	NN
647	3922	3924	of	of	IN
648	3925	3926	1	1	CD
650	3927	3929	SS	ss	NNP
651	3930	3939	antedated	antedate	JJ
652	3940	3943	the	the	DT
653	3944	3949	onset	onset	NN
654	3950	3952	of	of	IN
655	3953	3958	liver	liver	NN
656	3967	3974	disease	disease	NN
657	3975	3977	or	or	CC
658	3978	3981	its	its	PRP$
659	3982	3991	diagnosis	diagnosis	NN
661	3993	4000	Markers	marker	NNP
662	4001	4003	of	of	IN
663	4004	4009	viral	viral	JJ
664	4010	4019	hepatitis	hepatitis	NN
666	4029	4035	sought	seek	VBN
667	4036	4038	in	in	IN
668	4039	4041	39	39	CD
669	4042	4050	patients	patient	NNS
671	4052	4056	were	be	VBD
672	4057	4062	found	find	VBN
673	4063	4067	only	only	RB
674	4068	4070	in	in	IN
675	4071	4072	4	4	CD
677	4074	4077	Two	two	CD
678	4078	4086	patients	patient	NNS
679	4095	4102	carried	carry	VBD
680	4103	4106	the	the	DT
681	4107	4114	surface	surface	NN
682	4115	4122	antigen	antigen	NN
683	4123	4125	of	of	IN
684	4126	4135	hepatitis	hepatitis	NNP
686	4138	4143	virus	virus	NN
687	4144	4147	and	and	CC
688	4148	4151	one	one	CD
689	4160	4163	had	have	VBD
690	4164	4174	antibodies	antibody	NNS
691	4175	4177	to	to	TO
692	4178	4187	hepatitis	hepatitis	NNP
694	4190	4195	virus	virus	NN
696	4197	4199	In	in	IN
697	4200	4201	a	a	DT
698	4202	4207	liver	liver	NN
699	4208	4214	biopsy	biopsy	NN
700	4215	4217	of	of	IN
701	4218	4219	a	a	DT
702	4228	4235	patient	patient	NN
703	4236	4239	who	who	WP
704	4240	4246	lacked	lack	VBD
705	4247	4258	serological	serological	JJ
706	4259	4266	markers	marker	NNS
707	4267	4270	for	for	IN
708	4271	4280	hepatitis	hepatitis	NN
709	4289	4296	viruses	virus	NNS
711	4298	4307	hepatitis	hepatitis	NNP
713	4310	4315	virus	virus	NN
714	4316	4319	was	be	VBD
715	4320	4328	detected	detect	VBN
716	4329	4331	by	by	IN
717	4341	4343	in	in	IN
718	4344	4348	situ	situ	NN
719	4349	4362	hybridization	hybridization	NN
721	4372	4376	Risk	risk	NN
722	4377	4384	factors	factor	NNS
723	4385	4388	for	for	IN
724	4389	4394	liver	liver	NN
725	4395	4402	disease	disease	NN
726	4403	4407	were	be	VBD
727	4408	4418	identified	identify	VBN
728	4419	4421	in	in	IN
729	4422	4424	40	40	CD
731	4426	4428	of	of	IN
732	4437	4440	the	the	DT
733	4441	4449	patients	patient	NNS
734	4450	4454	with	with	IN
735	4455	4463	abnormal	abnormal	JJ
736	4464	4469	liver	liver	NN
737	4470	4478	function	function	NN
738	4479	4484	tests	test	NNS
739	4485	4488	and	and	CC
740	4489	4492	are	be	VBP
741	4501	4510	described	describe	VBN
742	4511	4513	in	in	IN
743	4514	4519	Table	table	NNP
744	4520	4521	4	4	CD
746	4523	4525	No	no	DT
747	4526	4537	association	association	NN
748	4538	4542	with	with	IN
749	4543	4550	tobacco	tobacco	NN
750	4551	4554	use	use	NN
751	4555	4558	was	be	VBD
752	4567	4572	found	find	VBN
754	4574	4578	Only	only	RB
755	4579	4580	5	5	CD
756	4581	4589	patients	patient	NNS
757	4590	4593	had	have	VBD
758	4594	4604	documented	document	VBN
759	4605	4613	evidence	evidence	NN
760	4614	4616	of	of	IN
761	4617	4624	tobacco	tobacco	NN
762	4633	4644	consumption	consumption	NN
764	4646	4648	We	we	PRP
765	4649	4654	found	find	VBD
766	4655	4657	no	no	DT
767	4658	4669	significant	significant	JJ
768	4670	4681	differences	difference	NNS
769	4682	4684	in	in	IN
770	4685	4689	risk	risk	NN
771	4698	4705	factors	factor	NNS
772	4706	4709	for	for	IN
773	4710	4718	abnormal	abnormal	JJ
774	4719	4724	liver	liver	NN
775	4725	4733	function	function	NN
776	4734	4739	tests	test	NNS
777	4740	4745	among	among	IN
778	4746	4754	patients	patient	NNS
779	4763	4767	with	with	IN
780	4768	4770	or	or	CC
781	4771	4778	without	without	IN
782	4779	4786	hepatic	hepatic	JJ
783	4787	4798	involvement	involvement	NN
785	4800	4809	Therefore	therefore	RB
787	4811	4813	in	in	IN
788	4814	4816	60	60	CD
790	4818	4820	of	of	IN
791	4829	4832	the	the	DT
792	4833	4841	patients	patient	NNS
793	4842	4846	with	with	IN
794	4847	4850	sub	sub	NN
795	4851	4859	clinical	clinical	JJ
796	4860	4862	or	or	CC
797	4863	4871	clinical	clinical	JJ
798	4872	4880	evidence	evidence	NN
799	4881	4883	of	of	IN
800	4892	4897	liver	liver	NN
801	4898	4905	disease	disease	NN
803	4907	4909	no	no	DT
804	4910	4915	clear	clear	JJ
805	4916	4927	explanation	explanation	NN
806	4928	4931	for	for	IN
807	4932	4935	the	the	DT
808	4936	4944	abnormal	abnormal	JJ
809	4945	4949	LFTs	lft	NNP
810	4958	4961	was	be	VBD
811	4962	4967	found	find	VBN
813	4969	4975	except	except	IN
814	4976	4979	for	for	IN
815	4980	4983	the	the	DT
816	4984	4995	association	association	NN
817	4996	5000	with	with	IN
818	5001	5002	1	1	CD
820	5003	5005	SS	ss	NNP
822	5015	5018	The	the	DT
823	5019	5026	pattern	pattern	NN
824	5027	5029	of	of	IN
825	5030	5041	biochemical	biochemical	JJ
826	5042	5047	liver	liver	NN
827	5048	5061	abnormalities	abnormality	NNS
828	5062	5065	was	be	VBD
829	5074	5080	mainly	mainly	RB
830	5081	5095	hepatocellular	hepatocellular	NN
832	5097	5104	defined	define	VBN
833	5105	5107	as	as	IN
834	5108	5119	predominant	predominant	NN
835	5120	5128	increase	increase	NN
836	5129	5131	of	of	IN
837	5140	5143	AST	ast	NNP
838	5144	5147	and	and	CC
840	5148	5150	or	or	CC
841	5151	5154	ALT	alt	NNP
842	5155	5157	in	in	IN
843	5158	5168	comparison	comparison	NN
844	5169	5173	with	with	IN
845	5174	5176	AP	ap	NNP
846	5177	5180	and	and	CC
848	5181	5183	or	or	CC
849	5184	5194	bilirubins	bilirubin	NNS
851	5196	5198	in	in	IN
852	5207	5209	11	11	CD
853	5210	5215	cases	case	NNS
855	5217	5228	cholestatic	cholestatic	JJ
857	5230	5237	defined	define	VBN
858	5238	5240	as	as	IN
859	5241	5252	predominant	predominant	NN
860	5253	5261	increase	increase	NN
861	5262	5264	in	in	IN
862	5273	5275	AP	ap	NNP
863	5276	5279	and	and	CC
865	5280	5282	or	or	CC
866	5283	5293	bilirubins	bilirubin	NNS
867	5294	5302	compared	compare	VBN
868	5303	5307	with	with	IN
869	5308	5311	AST	ast	NNP
870	5312	5315	and	and	CC
872	5316	5318	or	or	CC
873	5319	5322	ALT	alt	NNP
875	5324	5326	in	in	IN
876	5327	5328	3	3	CD
877	5329	5332	and	and	CC
878	5341	5346	mixed	mix	JJ
880	5348	5356	evidence	evidence	NN
881	5357	5359	of	of	IN
882	5360	5364	both	both	DT
883	5365	5376	cholestatic	cholestatic	JJ
884	5377	5380	and	and	CC
885	5381	5395	hepatocellular	hepatocellular	NN
886	5404	5410	damage	damage	NN
888	5412	5414	in	in	IN
889	5415	5416	8	8	CD
890	5417	5422	cases	case	NNS
892	5424	5437	Abnormalities	abnormality	NNP
893	5438	5442	were	be	VBD
894	5443	5453	persistent	persistent	JJ
896	5455	5462	present	present	JJ
897	5471	5473	on	on	IN
898	5474	5479	every	every	DT
899	5480	5488	occasion	occasion	NN
900	5489	5493	when	when	WRB
901	5494	5502	measured	measure	VBN
902	5503	5507	more	more	RBR
903	5508	5512	than	than	IN
904	5513	5517	once	once	RB
906	5519	5521	in	in	IN
907	5522	5524	19	19	CD
908	5533	5541	patients	patient	NNS
910	5543	5547	65.5	65.5	CD
912	5549	5551	of	of	IN
913	5552	5557	those	those	DT
914	5558	5562	with	with	IN
915	5563	5571	abnormal	abnormal	JJ
916	5572	5576	LFTs	lft	NNP
919	5579	5591	intermittent	intermittent	JJ
921	5601	5609	presence	presence	NN
922	5610	5612	of	of	IN
923	5613	5616	LFT	lft	NNP
924	5617	5630	abnormalities	abnormality	NNS
925	5631	5634	was	be	VBD
926	5635	5638	not	not	RB
927	5639	5644	found	find	VBN
928	5645	5647	in	in	IN
929	5648	5651	all	all	DT
930	5660	5674	determinations	determination	NNS
932	5676	5678	in	in	IN
933	5679	5680	9	9	CD
935	5682	5684	31	31	CD
938	5687	5690	and	and	CC
939	5691	5693	in	in	IN
940	5694	5697	one	one	CD
941	5698	5702	case	case	NN
943	5704	5707	3.5	3.5	CD
946	5710	5715	there	there	EX
947	5716	5719	was	be	VBD
948	5728	5732	only	only	RB
949	5733	5736	one	one	CD
950	5737	5750	determination	determination	NN
951	5751	5753	of	of	IN
952	5754	5759	liver	liver	NN
953	5760	5768	function	function	NN
954	5769	5774	tests	test	NNS
956	5776	5779	The	the	DT
957	5780	5787	pattern	pattern	NN
958	5796	5798	of	of	IN
959	5799	5804	liver	liver	NN
960	5805	5811	enzyme	enzyme	NN
961	5812	5825	abnormalities	abnormality	NNS
962	5826	5828	is	be	VBZ
963	5829	5834	shown	show	VBN
964	5835	5837	in	in	IN
965	5838	5844	Figure	figure	NN
966	5845	5846	1	1	CD
968	5848	5852	None	none	NN
969	5853	5855	of	of	IN
970	5864	5867	the	the	DT
971	5868	5876	patients	patient	NNS
972	5877	5881	with	with	IN
973	5882	5890	abnormal	abnormal	JJ
974	5891	5896	liver	liver	NN
975	5897	5905	function	function	NN
976	5906	5911	tests	test	NNS
977	5912	5915	had	have	VBD
978	5924	5932	clinical	clinical	JJ
979	5933	5941	evidence	evidence	NN
980	5942	5944	of	of	IN
981	5945	5951	muscle	muscle	NN
982	5952	5963	involvement	involvement	NN
983	5964	5968	that	that	WDT
984	5969	5974	could	could	MD
985	5975	5982	explain	explain	VB
986	5991	5994	the	the	DT
987	5995	5999	high	high	JJ
988	6000	6006	levels	level	NNS
989	6007	6009	of	of	IN
990	6010	6028	amino-transferases	amino-transferase	JJ
992	6030	6038	Activity	activity	NN
993	6039	6041	of	of	IN
994	6042	6045	CPK	cpk	NNP
995	6046	6048	or	or	CC
996	6057	6065	aldolase	aldolase	NN
997	6066	6069	was	be	VBD
998	6070	6073	not	not	RB
999	6074	6082	elevated	elevate	VBD
1000	6083	6087	when	when	WRB
1001	6088	6096	measured	measure	VBN
1002	6097	6099	in	in	IN
1003	6100	6102	15	15	CD
1004	6103	6105	of	of	IN
1005	6106	6109	the	the	DT
1006	6110	6112	29	29	CD
1007	6121	6129	patients	patient	NNS
1008	6130	6134	with	with	IN
1009	6135	6143	abnormal	abnormal	JJ
1010	6144	6149	liver	liver	NN
1011	6150	6158	function	function	NN
1012	6159	6164	tests	test	NNS
1014	6174	6192	Anti-mitochondrial	anti-mitochondrial	NNP
1015	6193	6203	antibodies	antibody	NNS
1017	6205	6208	AMA	ama	NNP
1019	6210	6213	and	and	CC
1020	6214	6225	anti-smooth	anti-smooth	JJ
1021	6226	6232	muscle	muscle	NN
1022	6241	6251	antibodies	antibody	NNS
1024	6253	6257	ASMA	asma	NNP
1026	6259	6263	were	be	VBD
1027	6264	6270	sought	seek	VBN
1028	6271	6273	in	in	IN
1029	6274	6275	5	5	CD
1030	6276	6284	patients	patient	NNS
1032	6286	6290	with	with	IN
1033	6291	6299	positive	positive	JJ
1034	6308	6312	ASMA	asma	NNP
1035	6313	6315	in	in	IN
1036	6316	6317	2	2	CD
1038	6327	6330	The	the	DT
1039	6331	6342	association	association	NN
1040	6343	6345	of	of	IN
1041	6346	6354	abnormal	abnormal	JJ
1042	6355	6360	liver	liver	NN
1043	6361	6369	function	function	NN
1044	6370	6375	tests	test	NNS
1045	6376	6380	with	with	IN
1046	6389	6394	other	other	JJ
1047	6395	6407	non-exocrine	non-exocrine	JJ
1048	6408	6416	features	feature	NNS
1049	6417	6419	of	of	IN
1050	6420	6421	1	1	CD
1052	6422	6424	SS	ss	NNP
1053	6425	6427	is	be	VBZ
1054	6428	6433	shown	show	VBN
1055	6434	6436	in	in	IN
1056	6437	6443	Figure	figure	NN
1057	6444	6445	2	2	CD
1059	6455	6463	Patients	patient	NNS
1060	6464	6468	with	with	IN
1061	6469	6477	abnormal	abnormal	JJ
1062	6478	6483	liver	liver	NN
1063	6484	6492	function	function	NN
1064	6493	6498	tests	test	NNS
1065	6499	6503	were	be	VBD
1066	6504	6508	more	more	RBR
1067	6517	6523	likely	likely	JJ
1068	6524	6526	to	to	TO
1069	6527	6531	have	have	VB
1070	6532	6536	lung	lung	NN
1072	6538	6544	kidney	kidney	NN
1073	6545	6547	or	or	CC
1074	6548	6561	hematological	hematological	JJ
1075	6570	6584	manifestations	manifestation	NNS
1077	6586	6590	when	when	WRB
1078	6591	6599	compared	compare	VBN
1079	6600	6602	to	to	TO
1080	6603	6610	Sjögren	sjögren	NNP
1082	6613	6621	patients	patient	NNS
1083	6622	6629	without	without	IN
1084	6638	6643	liver	liver	NN
1085	6644	6651	disease	disease	NN
1087	6653	6661	Presence	presence	NNP
1088	6662	6664	of	of	IN
1089	6665	6670	other	other	JJ
1090	6671	6683	non-exocrine	non-exocrine	JJ
1091	6684	6692	features	feature	NNS
1092	6693	6695	of	of	IN
1093	6704	6705	1	1	CD
1095	6706	6708	SS	ss	NNP
1096	6709	6712	was	be	VBD
1097	6713	6716	not	not	RB
1098	6717	6727	influenced	influence	VBN
1099	6728	6730	by	by	IN
1100	6731	6741	prevalence	prevalence	NN
1101	6742	6744	of	of	IN
1102	6745	6750	liver	liver	NN
1103	6759	6767	diseases	disease	NNS
1105	6777	6786	Regarding	regard	VBG
1106	6787	6797	laboratory	laboratory	NN
1107	6798	6802	test	test	NN
1108	6803	6810	results	result	NNS
1110	6812	6820	patients	patient	NNS
1111	6821	6825	with	with	IN
1112	6826	6831	liver	liver	NN
1113	6840	6847	disease	disease	NN
1114	6848	6852	were	be	VBD
1115	6853	6857	more	more	RBR
1116	6858	6864	likely	likely	JJ
1117	6865	6867	to	to	TO
1118	6868	6872	have	have	VB
1119	6873	6875	an	an	DT
1120	6876	6884	elevated	elevated	JJ
1121	6885	6898	sedimentation	sedimentation	NN
1122	6907	6911	rate	rate	NN
1123	6912	6914	at	at	IN
1124	6915	6919	some	some	DT
1125	6920	6925	point	point	NN
1126	6926	6932	during	during	IN
1127	6933	6936	the	the	DT
1128	6937	6943	course	course	NN
1129	6944	6946	of	of	IN
1130	6947	6952	their	their	PRP$
1131	6953	6960	disease	disease	NN
1134	6972	6980	positive	positive	JJ
1135	6981	6986	anti-	anti-	NN
1136	6986	6989	ENA	ena	NNP
1138	6991	6996	anti-	anti-	NN
1139	6996	6998	Ro	ro	NNP
1141	7000	7005	anti-	anti-	NN
1142	7005	7007	Ro	ro	NNP
1144	7008	7010	La	la	NNP
1146	7012	7015	and	and	CC
1148	7016	7018	or	or	CC
1149	7019	7024	anti-	anti-	NN
1150	7024	7027	RNP	rnp	NNP
1152	7037	7040	was	be	VBD
1153	7041	7045	also	also	RB
1154	7046	7056	associated	associate	VBN
1155	7057	7061	with	with	IN
1156	7062	7064	an	an	DT
1157	7065	7074	increased	increased	JJ
1158	7075	7085	prevalence	prevalence	NN
1159	7086	7088	of	of	IN
1160	7097	7105	abnormal	abnormal	JJ
1161	7106	7111	liver	liver	NN
1162	7112	7120	function	function	NN
1163	7121	7126	tests	test	NNS
1165	7128	7134	Figure	figure	NN
1166	7135	7136	3	3	CD
1169	7139	7142	The	the	DT
1170	7143	7149	sample	sample	NN
1171	7150	7153	was	be	VBD
1172	7162	7165	too	too	RB
1173	7166	7171	small	small	JJ
1174	7172	7174	to	to	TO
1175	7175	7184	determine	determine	VB
1176	7185	7192	whether	whether	IN
1177	7193	7194	a	a	DT
1178	7195	7203	specific	specific	JJ
1179	7204	7207	ENA	ena	NNP
1180	7208	7211	was	be	VBD
1181	7220	7230	associated	associate	VBN
1182	7231	7235	with	with	IN
1183	7236	7241	liver	liver	NN
1184	7242	7249	disease	disease	NN
1186	7251	7256	Other	other	JJ
1187	7257	7264	markers	marker	NNS
1188	7265	7267	of	of	IN
1189	7268	7276	systemic	systemic	JJ
1190	7285	7297	inflammation	inflammation	NN
1191	7298	7300	or	or	CC
1192	7301	7313	autoimmunity	autoimmunity	NN
1193	7314	7317	did	do	VBD
1194	7318	7321	not	not	RB
1195	7322	7331	correlate	correlate	VBP
1196	7332	7336	with	with	IN
1197	7337	7340	the	the	DT
1198	7349	7357	presence	presence	NN
1199	7358	7360	or	or	CC
1200	7361	7368	absence	absence	NN
1201	7369	7371	of	of	IN
1202	7372	7375	LFT	lft	NNP
1203	7376	7389	abnormalities	abnormality	NNS
1205	7399	7404	Liver	liver	NNP
1206	7405	7413	biopsies	biopsy	NNS
1208	7415	7419	done	do	VBN
1209	7420	7422	in	in	IN
1210	7423	7424	8	8	CD
1211	7425	7433	patients	patient	NNS
1213	7435	7444	disclosed	disclose	VBD
1214	7445	7455	post-viral	post-viral	JJ
1215	7464	7471	chronic	chronic	JJ
1216	7472	7478	active	active	JJ
1217	7479	7488	hepatitis	hepatitis	NN
1219	7490	7491	3	3	CD
1222	7494	7505	cryptogenic	cryptogenic	JJ
1223	7506	7515	cirrhosis	cirrhosis	NNS
1225	7517	7518	2	2	CD
1228	7529	7532	and	and	CC
1229	7533	7536	one	one	CD
1230	7537	7541	case	case	NN
1231	7542	7546	each	each	DT
1232	7547	7549	of	of	IN
1233	7550	7560	post-viral	post-viral	JJ
1234	7561	7570	cirrhosis	cirrhosis	NNS
1236	7572	7581	alcoholic	alcoholic	JJ
1237	7590	7599	hepatitis	hepatitis	NN
1239	7601	7604	and	and	CC
1240	7605	7615	autoimmune	autoimmune	JJ
1241	7616	7625	hepatitis	hepatitis	NN
1243	7649	7659	Discussion	discussion	NNP
1244	7668	7670	In	in	IN
1245	7671	7675	this	this	DT
1246	7676	7681	group	group	NN
1247	7682	7684	of	of	IN
1248	7685	7692	Sjögren	sjögren	NNP
1250	7695	7703	patients	patient	NNS
1251	7704	7708	seen	see	VBN
1252	7709	7711	at	at	IN
1253	7712	7713	a	a	DT
1254	7714	7722	tertiary	tertiary	JJ
1255	7731	7735	care	care	NN
1256	7736	7742	center	center	NN
1258	7744	7752	abnormal	abnormal	JJ
1259	7753	7758	liver	liver	NN
1260	7759	7767	function	function	NN
1261	7768	7773	tests	test	NNS
1262	7774	7778	were	be	VBD
1263	7779	7784	found	find	VBN
1264	7785	7787	to	to	TO
1265	7788	7790	be	be	VB
1266	7799	7800	a	a	DT
1267	7801	7807	common	common	JJ
1268	7808	7820	non-exocrine	non-exocrine	JJ
1269	7821	7828	feature	feature	NN
1270	7829	7831	of	of	IN
1271	7832	7833	1	1	CD
1273	7834	7836	SS	ss	NNP
1275	7838	7841	The	the	DT
1276	7842	7852	prevalence	prevalence	NN
1277	7853	7855	of	of	IN
1278	7864	7868	this	this	DT
1279	7869	7880	association	association	NN
1280	7881	7884	was	be	VBD
1281	7885	7890	found	find	VBN
1282	7891	7893	to	to	TO
1283	7894	7896	be	be	VB
1284	7897	7903	higher	higher	JJR
1285	7904	7906	in	in	IN
1286	7907	7910	our	our	PRP$
1287	7911	7916	study	study	NN
1288	7917	7921	than	than	IN
1289	7930	7932	in	in	IN
1290	7933	7938	other	other	JJ
1291	7939	7947	previous	previous	JJ
1292	7948	7954	series	series	NN
1294	7957	7958	2	2	CD
1295	7959	7960	3	3	CD
1296	7961	7962	4	4	CD
1297	7963	7964	5	5	CD
1298	7965	7966	6	6	CD
1299	7967	7968	7	7	CD
1302	7973	7976	The	the	DT
1303	7977	7981	true	true	JJ
1304	7990	8000	prevalence	prevalence	NN
1305	8001	8006	could	could	MD
1306	8007	8009	be	be	VB
1307	8010	8014	even	even	RB
1308	8015	8021	higher	higher	JJR
1309	8022	8027	since	since	IN
1310	8028	8033	liver	liver	NN
1311	8034	8040	enzyme	enzyme	NN
1312	8041	8049	profiles	profile	NNS
1313	8058	8062	were	be	VBD
1314	8063	8066	not	not	RB
1315	8067	8071	done	do	VBN
1316	8072	8074	in	in	IN
1317	8075	8078	all	all	DT
1318	8079	8087	patients	patient	NNS
1320	8089	8092	The	the	DT
1321	8093	8103	prevalence	prevalence	NN
1322	8104	8113	suggested	suggest	VBD
1323	8114	8116	in	in	IN
1324	8125	8133	previous	previous	JJ
1325	8134	8141	reports	report	NNS
1326	8142	8148	ranges	range	NNS
1327	8149	8153	from	from	IN
1328	8154	8155	6	6	CD
1329	8156	8158	to	to	TO
1330	8159	8161	58	58	CD
1333	8165	8168	but	but	CC
1334	8169	8172	the	the	DT
1335	8173	8183	definition	definition	NN
1336	8192	8194	of	of	IN
1337	8195	8202	hepatic	hepatic	JJ
1338	8203	8210	disease	disease	NN
1339	8211	8217	varies	vary	VBZ
1340	8218	8222	from	from	IN
1341	8223	8226	the	the	DT
1342	8227	8237	unspecific	unspecific	JJ
1344	8239	8243	e.g.	e.g.	NN
1345	8252	8264	hepatomegaly	hepatomegaly	RB
1347	8266	8268	to	to	TO
1348	8269	8273	well	well	RB
1349	8274	8280	proven	prove	VBN
1350	8281	8286	cases	case	NNS
1351	8287	8289	of	of	IN
1352	8290	8295	liver	liver	NN
1353	8296	8303	disease	disease	NN
1355	8306	8307	1	1	CD
1356	8308	8309	2	2	CD
1357	8310	8311	3	3	CD
1358	8320	8321	4	4	CD
1359	8322	8323	5	5	CD
1360	8324	8325	6	6	CD
1361	8326	8327	7	7	CD
1362	8328	8330	28	28	CD
1365	8335	8340	Denko	denko	NNP
1366	8341	8343	in	in	IN
1367	8344	8348	1960	1960	CD
1368	8349	8357	reported	report	VBD
1369	8358	8362	that	that	IN
1370	8363	8365	12	12	CD
1372	8367	8369	of	of	IN
1373	8370	8378	patients	patient	NNS
1374	8387	8391	with	with	IN
1375	8392	8394	SS	ss	NNP
1376	8395	8398	had	have	VBD
1377	8399	8417	hepatosplenomegaly	hepatosplenomegaly	RB
1379	8420	8422	29	29	CD
1382	8427	8432	Other	other	JJ
1383	8433	8440	studies	study	NNS
1384	8441	8445	done	do	VBN
1385	8454	8456	in	in	IN
1386	8457	8460	the	the	DT
1387	8461	8465	1960	1960	CD
1389	8468	8472	also	also	RB
1390	8473	8482	confirmed	confirm	VBD
1391	8483	8495	hepatomegaly	hepatomegaly	RB
1392	8496	8498	in	in	IN
1393	8499	8501	18	18	CD
1395	8502	8504	20	20	CD
1397	8506	8508	of	of	IN
1398	8517	8525	patients	patient	NNS
1399	8526	8530	with	with	IN
1400	8531	8533	SS	ss	NNP
1402	8536	8538	30	30	CD
1403	8539	8541	31	31	CD
1406	8546	8548	In	in	IN
1407	8549	8553	1970	1970	CD
1409	8555	8561	Whaley	whaley	NNP
1410	8562	8570	reported	report	VBD
1411	8571	8576	liver	liver	NN
1412	8585	8592	disease	disease	NN
1413	8593	8595	in	in	IN
1414	8596	8597	6	6	CD
1416	8599	8601	of	of	IN
1417	8602	8610	patients	patient	NNS
1418	8611	8615	with	with	IN
1419	8616	8618	SS	ss	NNP
1420	8619	8622	and	and	CC
1421	8623	8632	mentioned	mention	VBD
1422	8633	8635	an	an	DT
1423	8644	8655	association	association	NN
1424	8656	8660	with	with	IN
1425	8661	8679	anti-mitochondrial	anti-mitochondrial	JJ
1426	8680	8690	antibodies	antibody	NNS
1428	8693	8694	2	2	CD
1431	8699	8701	In	in	IN
1432	8710	8714	1986	1986	CD
1434	8716	8723	Tsianos	tsiano	NNP
1435	8724	8727	and	and	CC
1436	8728	8738	co-workers	co-worker	NNS
1437	8739	8748	described	describe	VBD
1438	8749	8751	22	22	CD
1439	8752	8754	SS	ss	NNP
1440	8755	8763	patients	patient	NNS
1441	8764	8768	with	with	IN
1442	8777	8793	gastrointestinal	gastrointestinal	NN
1443	8794	8807	complications	complication	NNS
1445	8809	8815	called	call	VBN
1446	8816	8820	from	from	IN
1447	8821	8822	a	a	DT
1448	8823	8828	large	large	JJ
1449	8829	8835	cohort	cohort	NN
1451	8845	8849	only	only	RB
1452	8850	8853	two	two	CD
1453	8854	8862	patients	patient	NNS
1454	8863	8866	had	have	VBD
1455	8867	8872	liver	liver	NN
1456	8873	8880	disease	disease	NN
1458	8882	8886	each	each	DT
1459	8887	8891	with	with	IN
1460	8892	8899	chronic	chronic	JJ
1461	8908	8914	active	active	JJ
1462	8915	8924	hepatitis	hepatitis	NN
1464	8927	8928	4	4	CD
1467	8933	8938	Other	other	JJ
1468	8939	8946	studies	study	NNS
1469	8947	8951	have	have	VBP
1470	8952	8960	reported	report	VBN
1471	8969	8977	variable	variable	JJ
1472	8978	8988	prevalence	prevalence	NN
1474	8991	8992	3	3	CD
1475	8993	8995	28	28	CD
1477	8998	9001	and	and	CC
1478	9002	9011	different	different	JJ
1479	9020	9037	histopathological	histopathological	JJ
1480	9038	9046	findings	finding	NNS
1481	9047	9049	in	in	IN
1482	9050	9055	liver	liver	NN
1483	9056	9064	biopsies	biopsy	NNS
1484	9065	9072	ranging	rang	VBG
1485	9073	9077	from	from	IN
1486	9086	9097	cholestatic	cholestatic	JJ
1487	9098	9103	liver	liver	NN
1488	9104	9110	damage	damage	NN
1490	9112	9117	stage	stage	NN
1491	9118	9119	I	i	PRP
1492	9120	9127	primary	primary	JJ
1493	9128	9135	biliary	biliary	JJ
1494	9144	9153	cirrhosis	cirrhosis	NNS
1496	9155	9157	to	to	TO
1497	9158	9165	chronic	chronic	JJ
1498	9166	9172	active	active	JJ
1499	9173	9182	hepatitis	hepatitis	NN
1500	9183	9186	due	due	JJ
1501	9187	9189	to	to	TO
1502	9190	9199	hepatitis	hepatitis	NNP
1504	9210	9215	virus	virus	NN
1506	9225	9227	In	in	IN
1507	9228	9231	our	our	PRP$
1508	9232	9237	study	study	NN
1510	9239	9244	liver	liver	NN
1511	9245	9252	disease	disease	NN
1512	9253	9256	was	be	VBD
1513	9257	9267	associated	associate	VBN
1514	9268	9272	with	with	IN
1515	9273	9278	other	other	JJ
1516	9287	9299	non-exocrine	non-exocrine	JJ
1517	9300	9314	manifestations	manifestation	NNS
1518	9315	9317	of	of	IN
1519	9318	9319	1	1	CD
1521	9320	9322	SS	ss	NNP
1523	9324	9336	specifically	specifically	RB
1524	9337	9342	those	those	DT
1525	9351	9360	affecting	affect	VBG
1526	9361	9365	lung	lung	NN
1528	9367	9373	kidney	kidney	NN
1529	9374	9377	and	and	CC
1530	9378	9383	blood	blood	NN
1531	9384	9389	cells	cell	NNS
1533	9391	9396	Those	those	DT
1534	9397	9405	patients	patient	NNS
1535	9406	9410	with	with	IN
1536	9419	9430	serological	serological	JJ
1537	9431	9439	evidence	evidence	NN
1538	9440	9442	of	of	IN
1539	9443	9451	systemic	systemic	JJ
1540	9452	9464	inflammation	inflammation	NN
1542	9466	9468	as	as	IN
1543	9469	9474	shown	show	VBN
1544	9475	9477	by	by	IN
1545	9486	9488	an	an	DT
1546	9489	9497	elevated	elevated	JJ
1547	9498	9511	sedimentation	sedimentation	NN
1548	9512	9516	rate	rate	NN
1550	9518	9522	were	be	VBD
1551	9523	9527	more	more	RBR
1552	9528	9534	likely	likely	JJ
1553	9535	9537	to	to	TO
1554	9538	9542	have	have	VB
1555	9551	9556	liver	liver	NN
1556	9557	9561	test	test	NN
1557	9562	9575	abnormalities	abnormality	NNS
1559	9577	9581	Also	also	RB
1561	9583	9586	the	the	DT
1562	9587	9595	presence	presence	NN
1563	9596	9598	of	of	IN
1564	9599	9600	a	a	DT
1565	9601	9609	positive	positive	JJ
1566	9618	9623	anti-	anti-	NN
1567	9623	9626	ENA	ena	NNP
1568	9627	9637	correlated	correlate	JJ
1569	9638	9648	positively	positively	RB
1570	9649	9653	with	with	IN
1571	9654	9661	hepatic	hepatic	JJ
1572	9662	9669	disease	disease	NN
1574	9671	9673	An	an	DT
1575	9682	9693	association	association	NN
1576	9694	9696	of	of	IN
1577	9697	9700	ENA	ena	NNP
1578	9701	9709	response	response	NN
1579	9710	9714	with	with	IN
1580	9715	9720	liver	liver	NN
1581	9721	9728	disease	disease	NN
1582	9729	9732	has	have	VBZ
1583	9733	9737	been	be	VBN
1584	9746	9755	described	describe	VBN
1585	9756	9758	in	in	IN
1586	9759	9767	children	child	NNS
1587	9768	9772	with	with	IN
1588	9773	9783	autoimmune	autoimmune	JJ
1589	9784	9793	hepatitis	hepatitis	NN
1591	9795	9800	where	where	WRB
1592	9809	9814	anti-	anti-	NN
1593	9814	9826	ENA-positive	ena-positive	NNP
1594	9827	9835	patients	patient	NNS
1595	9836	9848	demonstrated	demonstrate	VBD
1596	9849	9853	more	more	RBR
1597	9854	9860	severe	severe	JJ
1598	9861	9866	liver	liver	NN
1599	9875	9879	test	test	NN
1600	9880	9893	abnormalities	abnormality	NNS
1601	9894	9898	than	than	IN
1602	9899	9904	those	those	DT
1603	9905	9908	who	who	WP
1604	9909	9913	were	be	VBD
1605	9914	9919	anti-	anti-	NN
1606	9919	9931	ENA-negative	ena-negative	NNP
1608	9942	9944	32	32	CD
1611	9949	9951	In	in	IN
1612	9952	9959	another	another	DT
1613	9960	9965	study	study	NN
1615	9967	9968	a	a	DT
1616	9969	9971	15	15	CD
1618	9974	9976	of	of	IN
1619	9977	9985	patients	patient	NNS
1620	9986	9990	with	with	IN
1621	9991	9998	various	various	JJ
1622	10007	10014	chronic	chronic	JJ
1623	10015	10020	liver	liver	NN
1624	10021	10029	diseases	disease	NNS
1625	10030	10034	were	be	VBD
1626	10035	10040	found	find	VBN
1627	10041	10043	to	to	TO
1628	10044	10046	be	be	VB
1629	10047	10052	anti-	anti-	NN
1630	10052	10055	RNP	rnp	NNP
1631	10056	10064	positive	positive	JJ
1633	10075	10077	33	33	CD
1636	10090	10094	With	with	IN
1637	10095	10111	etiopathogenesis	etiopathogenesis	NNS
1638	10112	10114	of	of	IN
1639	10115	10116	1	1	CD
1641	10117	10119	SS	ss	NNP
1642	10120	10125	still	still	RB
1643	10126	10128	an	an	DT
1644	10129	10133	open	open	JJ
1645	10134	10142	question	question	NN
1647	10153	10155	34	34	CD
1650	10160	10161	a	a	DT
1651	10162	10170	possible	possible	JJ
1652	10171	10175	role	role	NN
1653	10176	10178	of	of	IN
1654	10179	10188	hepatitis	hepatitis	NNP
1656	10191	10196	virus	virus	NN
1658	10198	10201	HCV	hcv	NNP
1660	10203	10206	has	have	VBZ
1661	10207	10212	drawn	draw	VBN
1662	10221	10230	attention	attention	NN
1664	10232	10238	Recent	recent	JJ
1665	10239	10246	studies	study	NNS
1666	10247	10251	have	have	VBP
1667	10252	10261	mentioned	mention	VBN
1668	10262	10265	HCV	hcv	NNP
1669	10266	10275	incidence	incidence	NN
1670	10276	10278	in	in	IN
1671	10287	10295	patients	patient	NNS
1672	10296	10300	with	with	IN
1673	10301	10302	1	1	CD
1674	10302	10304	SS	ss	NNP
1675	10305	10312	ranging	rang	VBG
1676	10313	10317	from	from	IN
1677	10318	10320	14	14	CD
1679	10321	10323	19	19	CD
1682	10327	10329	11	11	CD
1683	10330	10332	12	12	CD
1684	10333	10335	16	16	CD
1685	10336	10338	18	18	CD
1686	10339	10341	21	21	CD
1689	10354	10364	Phenotypic	phenotypic	NNP
1690	10365	10381	characterization	characterization	NN
1691	10382	10384	of	of	IN
1692	10385	10388	the	the	DT
1693	10389	10394	minor	minor	JJ
1694	10395	10403	salivary	salivary	JJ
1695	10404	10410	glands	gland	NNS
1696	10419	10423	with	with	IN
1697	10424	10444	immunohistochemistry	immunohistochemistry	NN
1698	10445	10447	in	in	IN
1699	10448	10456	patients	patient	NNS
1700	10457	10461	with	with	IN
1701	10462	10471	hepatitis	hepatitis	NNP
1703	10482	10487	virus	virus	NN
1704	10488	10497	infection	infection	NN
1705	10498	10501	and	and	CC
1707	10502	10504	or	or	CC
1708	10505	10506	1	1	CD
1710	10507	10509	SS	ss	NNP
1711	10510	10513	has	have	VBZ
1712	10514	10519	given	give	VBN
1713	10520	10531	conflicting	conflict	JJ
1714	10532	10539	results	result	NNS
1716	10550	10552	14	14	CD
1717	10553	10555	15	15	CD
1719	10558	10562	Some	some	DT
1720	10563	10570	reports	report	NNS
1721	10571	10578	mention	mention	VBP
1722	10579	10583	that	that	IN
1723	10584	10587	the	the	DT
1724	10588	10596	salivary	salivary	JJ
1725	10597	10602	gland	gland	NN
1726	10611	10619	findings	finding	NNS
1727	10620	10623	are	be	VBP
1728	10624	10634	strikingly	strikingly	RB
1729	10635	10642	similar	similar	JJ
1730	10643	10645	in	in	IN
1731	10646	10654	patients	patient	NNS
1732	10655	10659	with	with	IN
1733	10660	10665	liver	liver	NN
1734	10674	10681	disease	disease	NN
1735	10682	10692	associated	associate	VBN
1736	10693	10697	with	with	IN
1737	10698	10701	HCV	hcv	NNP
1738	10702	10711	infection	infection	NN
1739	10712	10716	than	than	IN
1740	10717	10719	in	in	IN
1741	10720	10725	those	those	DT
1742	10726	10730	with	with	IN
1743	10739	10740	1	1	CD
1745	10741	10743	SS	ss	NNP
1747	10746	10748	12	12	CD
1750	10753	10758	while	while	IN
1751	10759	10765	others	other	NNS
1752	10766	10773	mention	mention	VBP
1753	10774	10785	distinctive	distinctive	JJ
1754	10786	10797	differences	difference	NNS
1755	10806	10813	between	between	IN
1756	10814	10818	both	both	DT
1757	10819	10825	groups	group	NNS
1758	10826	10835	regarding	regard	VBG
1759	10836	10841	focus	focus	NN
1760	10842	10847	score	score	NN
1762	10849	10859	expression	expression	NN
1763	10860	10862	of	of	IN
1764	10871	10878	surface	surface	NN
1765	10879	10886	markers	marker	NNS
1766	10887	10889	in	in	IN
1767	10890	10901	lymphocytes	lymphocyte	NNS
1768	10902	10914	infiltrating	infiltrate	VBG
1769	10915	10918	the	the	DT
1770	10919	10927	salivary	salivary	JJ
1771	10936	10942	glands	gland	NNS
1772	10943	10946	and	and	CC
1773	10947	10949	in	in	IN
1774	10950	10960	epithelial	epithelial	NN
1775	10961	10966	cells	cell	NNS
1777	10968	10970	as	as	RB
1778	10971	10975	well	well	RB
1779	10976	10978	as	as	IN
1780	10979	10990	differences	difference	NNS
1781	10991	10993	in	in	IN
1782	11002	11005	the	the	DT
1783	11006	11012	degree	degree	NN
1784	11013	11015	of	of	IN
1785	11016	11028	inflammation	inflammation	NN
1787	11031	11033	14	14	CD
1788	11034	11036	15	15	CD
1791	11041	11051	Transgenic	transgenic	NNP
1792	11052	11056	mice	mouse	NNS
1793	11065	11071	models	model	NNS
1794	11072	11076	that	that	WDT
1795	11077	11082	carry	carry	VBP
1796	11083	11086	the	the	DT
1797	11087	11090	HCV	hcv	NNP
1798	11091	11099	envelope	envelope	NN
1799	11100	11105	genes	gene	NNS
1800	11106	11113	develop	develop	VBP
1801	11114	11116	an	an	DT
1802	11125	11138	exocrinopathy	exocrinopathy	NN
1803	11139	11148	affecting	affect	VBG
1804	11149	11157	salivary	salivary	JJ
1805	11158	11161	and	and	CC
1806	11162	11171	lachrymal	lachrymal	NN
1807	11172	11178	glands	gland	NNS
1809	11181	11183	19	19	CD
1812	11196	11206	Expression	expression	NNP
1813	11207	11209	of	of	IN
1814	11210	11222	autoimmunity	autoimmunity	NN
1815	11223	11230	markers	marker	NNS
1816	11231	11235	also	also	RB
1817	11236	11241	tends	tend	VBZ
1818	11242	11244	to	to	TO
1819	11245	11251	differ	differ	VB
1820	11260	11267	between	between	IN
1821	11268	11281	HCV-infection	hcv-infection	NN
1822	11282	11285	and	and	CC
1823	11286	11287	1	1	CD
1825	11288	11290	SS	ss	NNP
1827	11292	11300	Positive	positive	JJ
1828	11301	11305	ENAs	ena	NNP
1829	11306	11309	are	be	VBP
1830	11310	11316	rarely	rarely	RB
1831	11325	11329	seen	see	VBN
1832	11330	11332	in	in	IN
1833	11333	11345	HCV-patients	hcv-patient	NNP
1835	11347	11351	Also	also	RB
1837	11353	11355	in	in	IN
1838	11356	11360	most	most	JJS
1839	11361	11366	cases	case	NNS
1840	11367	11372	sicca	sicca	NN
1841	11373	11381	symptoms	symptom	NNS
1842	11390	11393	are	be	VBP
1843	11394	11397	not	not	RB
1844	11398	11405	present	present	JJ
1845	11406	11408	in	in	IN
1846	11409	11420	individuals	individual	NNS
1847	11421	11425	with	with	IN
1848	11426	11429	HCV	hcv	NNP
1849	11430	11432	as	as	IN
1850	11433	11441	compared	compare	VBN
1851	11442	11446	with	with	IN
1852	11455	11458	the	the	DT
1853	11459	11460	1	1	CD
1855	11461	11463	SS	ss	NNP
1856	11464	11474	population	population	NN
1858	11476	11484	Although	although	IN
1859	11485	11488	the	the	DT
1860	11489	11499	prevalence	prevalence	NN
1861	11500	11502	of	of	IN
1862	11503	11508	viral	viral	JJ
1863	11517	11526	hepatitis	hepatitis	NN
1864	11527	11534	markers	marker	NNS
1865	11535	11537	in	in	IN
1866	11538	11541	our	our	PRP$
1867	11542	11547	group	group	NN
1868	11548	11550	of	of	IN
1869	11551	11559	patients	patient	NNS
1870	11560	11564	with	with	IN
1871	11565	11570	liver	liver	NN
1872	11579	11586	disease	disease	NN
1873	11587	11590	was	be	VBD
1874	11591	11595	very	very	RB
1875	11596	11599	low	low	JJ
1876	11600	11603	and	and	CC
1877	11604	11607	did	do	VBD
1878	11608	11611	not	not	RB
1879	11612	11619	account	account	VB
1880	11620	11623	for	for	IN
1881	11624	11628	most	most	JJS
1882	11629	11631	of	of	IN
1883	11632	11635	the	the	DT
1884	11644	11649	cases	case	NNS
1885	11650	11654	with	with	IN
1886	11655	11663	abnormal	abnormal	JJ
1887	11664	11669	liver	liver	NN
1888	11670	11678	function	function	NN
1889	11679	11684	tests	test	NNS
1891	11686	11691	these	these	DT
1892	11692	11699	markers	marker	NNS
1893	11708	11712	were	be	VBD
1894	11713	11716	not	not	RB
1895	11717	11723	sought	seek	VBN
1896	11724	11726	in	in	IN
1897	11727	11728	a	a	DT
1898	11729	11734	small	small	JJ
1899	11735	11745	percentage	percentage	NN
1900	11746	11748	of	of	IN
1901	11749	11754	these	these	DT
1902	11755	11763	patients	patient	NNS
1904	11765	11767	It	it	PRP
1905	11776	11778	is	be	VBZ
1906	11779	11788	important	important	JJ
1907	11789	11791	to	to	TO
1908	11792	11796	note	note	VB
1909	11797	11801	that	that	IN
1910	11802	11805	HCV	hcv	NNP
1911	11806	11813	appears	appear	VBZ
1912	11814	11816	to	to	TO
1913	11817	11824	account	account	VB
1914	11825	11828	for	for	IN
1915	11829	11830	a	a	DT
1916	11839	11847	subgroup	subgroup	NN
1917	11848	11850	of	of	IN
1918	11851	11859	patients	patient	NNS
1919	11860	11864	with	with	IN
1920	11865	11873	exocrine	exocrine	NN
1921	11874	11884	complaints	complaint	NNS
1922	11885	11887	in	in	IN
1923	11888	11893	which	which	WDT
1924	11894	11898	half	half	PDT
1925	11907	11910	the	the	DT
1926	11911	11916	cases	case	NNS
1927	11917	11922	might	may	MD
1928	11923	11927	meet	meet	VB
1929	11928	11931	the	the	DT
1930	11932	11942	definition	definition	NN
1931	11943	11946	for	for	IN
1932	11947	11949	SS	ss	NNP
1933	11950	11959	according	accord	VBG
1934	11960	11962	to	to	TO
1935	11971	11979	European	european	JJ
1936	11980	11983	and	and	CC
1937	11984	11993	Manthorpe	manthorpe	NNP
1938	11994	12002	criteria	criterion	NNS
1940	12004	12011	However	however	RB
1942	12013	12017	this	this	DT
1943	12018	12026	subgroup	subgroup	NN
1944	12027	12029	is	be	VBZ
1945	12038	12051	characterized	characterize	VBN
1946	12052	12054	by	by	IN
1947	12055	12058	the	the	DT
1948	12059	12066	absence	absence	NN
1949	12067	12069	of	of	IN
1950	12070	12078	clinical	clinical	JJ
1951	12079	12093	manifestations	manifestation	NNS
1952	12102	12110	observed	observe	VBD
1953	12111	12113	in	in	IN
1954	12114	12115	1	1	CD
1956	12116	12118	SS	ss	NNP
1958	12120	12123	and	and	CC
1959	12124	12127	the	the	DT
1960	12128	12135	absence	absence	NN
1961	12136	12138	of	of	IN
1962	12139	12144	anti-	anti-	NN
1963	12144	12146	Ro	ro	NNP
1964	12147	12150	and	and	CC
1965	12151	12156	anti-	anti-	NN
1966	12156	12158	La	la	NNP
1968	12169	12171	35	35	CD
1971	12184	12186	An	an	DT
1972	12187	12195	aberrant	aberrant	NN
1973	12196	12207	interaction	interaction	NN
1974	12208	12215	between	between	IN
1975	12216	12227	lymphocytes	lymphocyte	NNS
1976	12228	12231	and	and	CC
1977	12240	12249	different	different	JJ
1978	12250	12260	epithelial	epithelial	NN
1979	12261	12268	tissues	tissue	NNS
1980	12269	12272	has	have	VBZ
1981	12273	12277	been	be	VBN
1982	12278	12286	proposed	propose	VBN
1983	12287	12289	as	as	IN
1984	12290	12291	a	a	DT
1985	12300	12309	mechanism	mechanism	NN
1986	12310	12313	for	for	IN
1987	12314	12317	the	the	DT
1988	12318	12324	damage	damage	NN
1989	12325	12329	seen	see	VBN
1990	12330	12332	in	in	IN
1991	12333	12342	different	different	JJ
1992	12343	12349	organs	organ	NNS
1993	12350	12352	in	in	IN
1994	12353	12354	1	1	CD
1996	12356	12358	SS	ss	NNP
1998	12369	12371	36	36	CD
2001	12376	12381	Since	since	IN
2002	12382	12384	it	it	PRP
2003	12385	12388	has	have	VBZ
2004	12389	12393	been	be	VBN
2005	12394	12403	suggested	suggest	VBN
2006	12404	12408	that	that	IN
2007	12409	12412	the	the	DT
2008	12413	12419	target	target	NN
2009	12420	12426	tissue	tissue	NN
2010	12435	12443	involved	involve	VBN
2011	12444	12446	in	in	IN
2012	12447	12450	the	the	DT
2013	12451	12461	autoimmune	autoimmune	JJ
2014	12462	12477	histopathologic	histopathologic	JJ
2015	12478	12485	lesions	lesion	NNS
2016	12486	12488	of	of	IN
2017	12489	12490	1	1	CD
2019	12491	12493	SS	ss	NNP
2020	12502	12507	might	may	MD
2021	12508	12510	be	be	VB
2022	12511	12514	the	the	DT
2023	12515	12525	epithelium	epithelium	NN
2025	12528	12530	37	37	CD
2028	12535	12537	it	it	PRP
2029	12538	12540	is	be	VBZ
2030	12541	12552	interesting	interest	JJ
2031	12553	12557	that	that	IN
2032	12558	12561	the	the	DT
2033	12570	12578	findings	finding	NNS
2034	12579	12581	in	in	IN
2035	12582	12585	our	our	PRP$
2036	12586	12591	study	study	NN
2037	12592	12597	point	point	NN
2038	12598	12600	to	to	TO
2039	12601	12604	the	the	DT
2040	12605	12616	association	association	NN
2041	12617	12619	of	of	IN
2042	12620	12625	liver	liver	NN
2043	12634	12641	disease	disease	NN
2044	12642	12646	with	with	IN
2045	12647	12656	pulmonary	pulmonary	JJ
2046	12657	12660	and	and	CC
2047	12661	12666	renal	renal	JJ
2048	12667	12680	abnormalities	abnormality	NNS
2050	12682	12685	all	all	DT
2051	12686	12691	which	which	WDT
2052	12700	12703	are	be	VBP
2053	12704	12717	characterized	characterize	VBN
2054	12718	12720	by	by	IN
2055	12721	12731	epithelial	epithelial	NN
2056	12732	12738	damage	damage	NN
2058	12741	12743	38	38	CD
2059	12744	12746	39	39	CD
2062	12759	12769	Epithelial	epithelial	NNP
2063	12770	12775	cells	cell	NNS
2064	12776	12780	have	have	VBP
2065	12781	12785	been	be	VBN
2066	12786	12794	proposed	propose	VBN
2067	12795	12797	to	to	TO
2068	12798	12800	be	be	VB
2069	12801	12807	active	active	JJ
2070	12816	12828	participants	participant	NNS
2071	12829	12835	rather	rather	RB
2072	12836	12840	than	than	IN
2073	12841	12848	passive	passive	JJ
2074	12849	12856	targets	target	NNS
2075	12857	12859	in	in	IN
2076	12860	12863	the	the	DT
2077	12864	12871	chronic	chronic	JJ
2078	12880	12886	immune	immune	JJ
2079	12887	12895	response	response	NN
2080	12896	12898	in	in	IN
2081	12899	12900	1	1	CD
2083	12901	12903	SS	ss	NNP
2084	12904	12907	but	but	CC
2085	12908	12915	further	further	JJ
2086	12916	12923	studies	study	NNS
2087	12924	12927	are	be	VBP
2088	12928	12934	needed	need	VBN
2089	12935	12937	to	to	TO
2090	12946	12955	establish	establish	VB
2091	12956	12959	the	the	DT
2092	12960	12964	role	role	NN
2093	12965	12967	of	of	IN
2094	12968	12973	liver	liver	NN
2095	12974	12984	epithelial	epithelial	NN
2096	12985	12990	cells	cell	NNS
2097	12991	12993	in	in	IN
2098	12994	12997	the	the	DT
2099	13006	13018	pathogenesis	pathogenesis	NNS
2100	13019	13021	of	of	IN
2101	13022	13029	hepatic	hepatic	JJ
2102	13030	13036	damage	damage	NN
2103	13037	13039	in	in	IN
2104	13040	13044	this	this	DT
2105	13045	13052	disease	disease	NN
2107	13054	13063	including	include	VBG
2108	13072	13075	the	the	DT
2109	13076	13084	analysis	analysis	NN
2110	13085	13087	of	of	IN
2111	13088	13091	HLA	hlum	NNP
2112	13092	13102	expression	expression	NN
2113	13103	13106	and	and	CC
2114	13107	13115	cytokine	cytokine	NN
2115	13116	13125	secretion	secretion	NN
2116	13134	13141	pattern	pattern	NN
2117	13142	13144	in	in	IN
2118	13145	13150	these	these	DT
2119	13151	13156	cells	cell	NNS
2121	13166	13169	The	the	DT
2122	13170	13182	co-existence	co-existence	NN
2123	13183	13185	of	of	IN
2124	13186	13191	liver	liver	NN
2125	13192	13199	disease	disease	NN
2126	13200	13203	and	and	CC
2127	13204	13207	the	the	DT
2128	13208	13216	presence	presence	NN
2129	13217	13219	of	of	IN
2130	13228	13239	circulating	circulate	VBG
2131	13240	13244	AMAs	ama	NNP
2132	13245	13247	in	in	IN
2133	13248	13255	Sjögren	sjögren	NNP
2135	13258	13266	patients	patient	NNS
2136	13267	13271	sera	serum	NN
2137	13272	13275	has	have	VBZ
2138	13276	13280	been	be	VBN
2139	13289	13296	pointed	point	VBN
2140	13297	13299	as	as	IN
2141	13300	13302	an	an	DT
2142	13303	13312	indicator	indicator	NN
2143	13313	13317	that	that	DT
2144	13318	13323	liver	liver	NN
2145	13324	13333	pathology	pathology	NN
2146	13334	13339	might	may	MD
2147	13340	13342	be	be	VB
2148	13351	13361	autoimmune	autoimmune	JJ
2149	13362	13365	and	and	CC
2150	13366	13373	similar	similar	JJ
2151	13374	13376	to	to	TO
2152	13377	13381	that	that	DT
2153	13382	13384	of	of	IN
2154	13385	13392	primary	primary	JJ
2155	13393	13400	biliary	biliary	JJ
2156	13401	13410	cirrhosis	cirrhosis	NNS
2158	13421	13422	4	4	CD
2159	13423	13424	7	7	CD
2160	13425	13426	8	8	CD
2161	13427	13429	10	10	CD
2164	13434	13436	In	in	IN
2165	13437	13445	previous	previous	JJ
2166	13446	13453	studies	study	NNS
2168	13455	13456	a	a	DT
2169	13457	13471	pericholangial	pericholangial	NN
2170	13480	13491	lymphocytic	lymphocytic	JJ
2171	13492	13504	infiltration	infiltration	NN
2172	13505	13512	similar	similar	JJ
2173	13513	13515	to	to	TO
2174	13516	13520	that	that	DT
2175	13521	13526	found	find	VBD
2176	13527	13529	in	in	IN
2177	13530	13535	stage	stage	NN
2178	13536	13537	I	i	PRP
2179	13546	13548	of	of	IN
2180	13549	13556	primary	primary	JJ
2181	13557	13564	biliary	biliary	JJ
2182	13565	13574	cirrhosis	cirrhosis	NNS
2184	13576	13579	has	have	VBZ
2185	13580	13584	been	be	VBN
2186	13585	13593	reported	report	VBN
2187	13594	13596	in	in	IN
2188	13597	13598	1	1	CD
2190	13599	13601	SS	ss	NNP
2191	13610	13614	with	with	IN
2192	13615	13623	abnormal	abnormal	JJ
2193	13624	13629	liver	liver	NN
2194	13630	13638	function	function	NN
2195	13639	13644	tests	test	NNS
2196	13645	13647	or	or	CC
2197	13648	13658	positivity	positivity	NN
2198	13659	13662	for	for	IN
2199	13663	13666	AMA	ama	NNP
2201	13677	13678	4	4	CD
2202	13679	13680	7	7	CD
2205	13685	13687	In	in	IN
2206	13688	13691	our	our	PRP$
2207	13692	13698	review	review	NN
2208	13699	13701	of	of	IN
2209	13702	13707	cases	case	NNS
2211	13709	13711	we	we	PRP
2212	13712	13717	found	find	VBD
2213	13718	13730	predominance	predominance	NN
2214	13731	13733	in	in	IN
2215	13742	13756	hepatocellular	hepatocellular	NN
2216	13757	13762	liver	liver	NN
2217	13763	13769	damage	damage	NN
2218	13770	13776	rather	rather	RB
2219	13777	13781	than	than	IN
2220	13782	13793	cholestatic	cholestatic	JJ
2221	13802	13809	disease	disease	NN
2223	13811	13816	which	which	WDT
2224	13817	13822	would	would	MD
2225	13823	13828	argue	argue	VB
2226	13829	13836	against	against	IN
2227	13837	13838	a	a	DT
2228	13839	13847	PBC-type	pbc-type	NNP
2229	13848	13850	of	of	IN
2230	13851	13856	liver	liver	NN
2231	13865	13871	damage	damage	NN
2233	13873	13878	Other	other	JJ
2234	13879	13886	authors	author	NNS
2235	13887	13890	had	have	VBD
2236	13891	13899	proposed	propose	VBN
2237	13900	13904	that	that	IN
2238	13905	13907	SS	ss	NNP
2239	13908	13918	associated	associate	VBN
2240	13919	13923	with	with	IN
2241	13932	13935	PBC	pbc	NNP
2242	13936	13942	should	should	MD
2243	13943	13945	be	be	VB
2244	13946	13956	considered	consider	VBN
2245	13957	13958	a	a	DT
2246	13959	13963	form	form	NN
2247	13964	13966	of	of	IN
2248	13967	13976	secondary	secondary	JJ
2249	13977	13979	SS	ss	NNP
2250	13980	13984	that	that	WDT
2251	13993	14002	resembles	resemble	VBZ
2252	14003	14007	more	more	JJR
2253	14008	14011	the	the	DT
2255	14013	14018	sicca	sicca	NN
2256	14019	14026	complex	complex	JJ
2258	14028	14032	with	with	IN
2259	14033	14041	exocrine	exocrine	NN
2260	14042	14050	features	feature	NNS
2261	14059	14063	seen	see	VBN
2262	14064	14066	in	in	IN
2263	14067	14075	patients	patient	NNS
2264	14076	14080	with	with	IN
2265	14081	14091	rheumatoid	rheumatoid	NN
2266	14092	14101	arthritis	arthritis	NN
2268	14104	14106	40	40	CD
2269	14107	14109	41	41	CD
2272	14122	14133	Limitations	limitation	NNPS
2273	14134	14136	of	of	IN
2274	14137	14140	the	the	DT
2275	14141	14146	study	study	NN
2276	14147	14151	come	come	VB
2277	14152	14161	primarily	primarily	RB
2278	14162	14166	from	from	IN
2279	14167	14172	being	be	VBG
2280	14173	14174	a	a	DT
2281	14183	14196	retrospective	retrospective	NN
2282	14197	14205	analysis	analysis	NN
2284	14207	14212	Since	since	IN
2285	14213	14216	the	the	DT
2286	14217	14225	patients	patient	NNS
2287	14226	14230	were	be	VBD
2288	14231	14238	studied	study	VBN
2289	14239	14241	in	in	IN
2290	14250	14251	a	a	DT
2291	14252	14260	tertiary	tertiary	JJ
2292	14261	14265	care	care	NN
2293	14266	14274	referral	referral	NN
2294	14275	14281	center	center	NN
2296	14283	14286	the	the	DT
2297	14287	14295	severity	severity	NN
2298	14296	14298	of	of	IN
2299	14299	14302	the	the	DT
2300	14311	14318	disease	disease	NN
2301	14319	14322	and	and	CC
2302	14323	14326	the	the	DT
2303	14327	14337	prevalence	prevalence	NN
2304	14338	14340	of	of	IN
2305	14341	14344	the	the	DT
2306	14345	14359	manifestations	manifestation	NNS
2307	14360	14365	might	may	MD
2308	14366	14368	be	be	VB
2309	14377	14386	different	different	JJ
2310	14387	14391	from	from	IN
2311	14392	14395	the	the	DT
2312	14396	14403	general	general	JJ
2313	14404	14405	1	1	CD
2315	14406	14408	SS	ss	NNP
2316	14409	14419	population	population	NN
2318	14421	14432	Furthermore	furthermore	RB
2320	14434	14436	in	in	IN
2321	14445	14449	many	many	JJ
2322	14450	14455	cases	case	NNS
2324	14457	14464	Sjögren	sjögren	NNP
2326	14467	14475	syndrome	syndrome	NN
2327	14476	14485	diagnosis	diagnosis	NN
2328	14486	14489	had	have	VBD
2329	14490	14494	been	be	VBN
2330	14495	14501	sought	seek	VBN
2331	14510	14517	because	because	IN
2332	14518	14520	of	of	IN
2333	14521	14530	otherwise	otherwise	RB
2334	14531	14542	unexplained	unexplain	JJ
2335	14543	14555	non-exocrine	non-exocrine	JJ
2336	14556	14564	features	feature	NNS
2338	14574	14579	While	while	IN
2339	14580	14582	we	we	PRP
2340	14583	14588	could	could	MD
2341	14589	14592	not	not	RB
2342	14593	14597	find	find	VB
2343	14598	14600	an	an	DT
2344	14601	14612	association	association	NN
2345	14613	14620	between	between	IN
2346	14621	14624	use	use	NN
2347	14625	14627	of	of	IN
2348	14636	14642	NSAIDS	nsaid	NNP
2349	14643	14645	or	or	CC
2350	14646	14651	other	other	JJ
2351	14652	14663	medications	medication	NNS
2352	14664	14667	and	and	CC
2353	14668	14678	prevalence	prevalence	NN
2354	14679	14681	of	of	IN
2355	14682	14687	liver	liver	NN
2356	14696	14704	function	function	NN
2357	14705	14710	tests	test	VBZ
2358	14711	14724	abnormalities	abnormality	NNS
2360	14726	14729	the	the	DT
2361	14730	14735	study	study	NN
2362	14736	14742	design	design	NN
2363	14743	14746	did	do	VBD
2364	14747	14750	not	not	RB
2365	14759	14764	allow	allow	VB
2366	14765	14767	us	us	PRP
2367	14768	14770	to	to	TO
2368	14771	14778	exclude	exclude	VB
2369	14779	14782	the	the	DT
2370	14783	14794	possibility	possibility	NN
2371	14795	14797	of	of	IN
2372	14798	14814	over-the-counter	over-the-counter	JJ
2374	14824	14827	OTC	otc	NNP
2376	14829	14839	medication	medication	NN
2377	14840	14843	use	use	NN
2378	14844	14848	that	that	WDT
2379	14849	14854	could	could	MD
2380	14855	14859	have	have	VB
2381	14860	14868	affected	affect	VBN
2382	14869	14872	LFT	lft	NNP
2384	14883	14894	measurement	measurement	NN
2386	14896	14900	Drug	drug	NN
2387	14901	14909	toxicity	toxicity	NN
2388	14910	14912	is	be	VBZ
2389	14913	14922	certainly	certainly	RB
2390	14923	14925	an	an	DT
2391	14926	14935	important	important	JJ
2392	14936	14942	factor	factor	NN
2393	14951	14953	to	to	TO
2394	14954	14956	be	be	VB
2395	14957	14967	considered	consider	VBN
2397	14969	14976	However	however	RB
2399	14978	14983	given	give	VBN
2400	14984	14988	that	that	IN
2401	14989	14993	most	most	JJS
2402	14994	15002	patients	patient	NNS
2403	15003	15006	had	have	VBD
2404	15015	15025	persistent	persistent	JJ
2405	15026	15032	rather	rather	RB
2406	15033	15037	than	than	IN
2407	15038	15050	intermittent	intermittent	JJ
2408	15051	15064	abnormalities	abnormality	NNS
2409	15065	15067	of	of	IN
2410	15068	15072	LFTs	lft	NNP
2411	15081	15084	and	and	CC
2412	15085	15089	that	that	IN
2413	15090	15093	the	the	DT
2414	15094	15097	use	use	NN
2415	15098	15100	of	of	IN
2416	15101	15112	hepatotoxic	hepatotoxic	JJ
2417	15113	15118	drugs	drug	NNS
2418	15119	15122	was	be	VBD
2419	15123	15126	not	not	RB
2420	15127	15135	elicited	elicit	JJ
2421	15136	15138	in	in	IN
2422	15147	15150	the	the	DT
2423	15151	15159	majority	majority	NN
2424	15160	15162	of	of	IN
2425	15163	15171	patients	patient	NNS
2426	15172	15176	with	with	IN
2427	15177	15182	liver	liver	NN
2428	15183	15196	abnormalities	abnormality	NNS
2430	15198	15199	a	a	DT
2431	15200	15205	toxic	toxic	JJ
2432	15214	15220	effect	effect	NN
2433	15221	15223	of	of	IN
2434	15224	15235	medications	medication	NNS
2435	15236	15241	could	could	MD
2436	15242	15245	not	not	RB
2437	15246	15248	be	be	VB
2438	15249	15260	established	establish	VBN
2440	15284	15295	Conclusions	conclusion	NNP
2441	15304	15309	Based	base	VBN
2442	15310	15312	on	on	IN
2443	15313	15316	the	the	DT
2444	15317	15324	results	result	NNS
2445	15325	15327	of	of	IN
2446	15328	15332	this	this	DT
2447	15333	15338	study	study	NN
2449	15340	15342	we	we	PRP
2450	15343	15351	consider	consider	VBP
2451	15352	15356	that	that	IN
2452	15357	15359	an	an	DT
2453	15368	15378	evaluation	evaluation	NN
2454	15379	15382	for	for	IN
2455	15383	15391	clinical	clinical	JJ
2456	15392	15395	and	and	CC
2457	15396	15407	serological	serological	JJ
2458	15408	15416	evidence	evidence	NN
2459	15417	15419	of	of	IN
2460	15420	15425	liver	liver	NN
2461	15434	15441	disease	disease	NN
2462	15442	15448	should	should	MD
2463	15449	15451	be	be	VB
2464	15452	15456	done	do	VBN
2465	15457	15459	in	in	IN
2466	15460	15465	every	every	DT
2467	15466	15473	patient	patient	NN
2468	15474	15478	with	with	IN
2469	15479	15480	1	1	CD
2471	15481	15483	SS	ss	NNP
2473	15493	15505	particularly	particularly	RB
2474	15506	15508	if	if	IN
2475	15509	15514	there	there	EX
2476	15515	15517	is	be	VBZ
2477	15518	15526	evidence	evidence	NN
2478	15527	15529	of	of	IN
2479	15530	15535	other	other	JJ
2480	15536	15548	non-exocrine	non-exocrine	JJ
2481	15557	15570	complications	complication	NNS
2482	15571	15573	or	or	CC
2483	15574	15585	serological	serological	JJ
2484	15586	15594	evidence	evidence	NN
2485	15595	15597	of	of	IN
2486	15598	15606	systemic	systemic	JJ
2487	15615	15627	inflammation	inflammation	NN
2489	15629	15637	Although	although	IN
2490	15638	15640	no	no	DT
2491	15641	15646	other	other	JJ
2492	15647	15656	diagnosis	diagnosis	NN
2493	15657	15667	explaining	explain	VBG
2494	15668	15673	liver	liver	NN
2495	15682	15689	disease	disease	NN
2496	15690	15693	may	may	MD
2497	15694	15696	be	be	VB
2498	15697	15702	found	find	VBN
2500	15704	15707	the	the	DT
2501	15708	15717	disorders	disorder	NNS
2502	15718	15721	for	for	IN
2503	15722	15727	which	which	WDT
2504	15728	15737	treatment	treatment	NN
2505	15746	15751	might	may	MD
2506	15752	15754	be	be	VB
2507	15755	15765	beneficial	beneficial	JJ
2509	15767	15771	e.g.	e.g.	NN
2510	15772	15790	immunosuppressants	immunosuppressant	NNS
2511	15791	15794	for	for	IN
2512	15795	15805	autoimmune	autoimmune	JJ
2513	15814	15823	hepatitis	hepatitis	NN
2515	15825	15841	interferon-alpha	interferon-alpha	JJ
2516	15842	15845	for	for	IN
2517	15846	15851	viral	viral	JJ
2518	15852	15861	hepatitis	hepatitis	NN
2520	15871	15885	ursodeoxycolic	ursodeoxycolic	JJ
2521	15886	15890	acid	acid	NN
2522	15891	15894	for	for	IN
2523	15895	15902	primary	primary	JJ
2524	15903	15910	biliary	biliary	JJ
2525	15911	15920	cirrhosis	cirrhosis	NNS
2527	15922	15929	warrant	warrant	NN
2528	15938	15939	a	a	DT
2529	15940	15948	diligent	diligent	NN
2530	15949	15955	search	search	NN
2531	15956	15958	in	in	IN
2532	15959	15962	all	all	DT
2533	15963	15968	cases	case	NNS
2534	15969	15971	of	of	IN
2535	15972	15973	1	1	CD
2537	15974	15976	SS	ss	NNP
2538	15977	15981	with	with	IN
2539	15982	15990	abnormal	abnormal	JJ
2540	15991	15996	liver	liver	NN
2541	16005	16013	function	function	NN
2543	16037	16046	Competing	compete	VBG
2544	16047	16056	interests	interest	NNS
2545	16065	16069	None	none	NN
2547	16093	16100	Authors	author	NNP
2549	16102	16115	contributions	contribution	NNS
2550	16124	16128	Both	both	DT
2551	16129	16136	authors	author	NNS
2552	16137	16148	contributed	contribute	VBD
2553	16149	16156	equally	equally	RB
2554	16157	16159	to	to	TO
2555	16160	16163	the	the	DT
2556	16164	16169	paper	paper	NN
